The historical rank and industry rank for HTG Molecular Diagnostics's Gross Margin % or its related term are showing as below:
HTGMQ's Gross Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 50.45 * Ranked among companies with meaningful Gross Margin % only.
HTG Molecular Diagnostics had a gross margin of -11.33% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
HTG Molecular Diagnostics had a gross margin of -11.33% for the quarter that ended in Mar. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
HTG Molecular Diagnostics Gross Margin % Related Terms
HTG Molecular Diagnostics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HTGMQ vs ABMC, TMO, DHR: Gross Margin % Comparison
For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HTG Molecular Diagnostics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where HTG Molecular Diagnostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
HTG Molecular Diagnostics (HTGMQ) has a Gross Margin % of -11.33% as of Mar. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on HTG Molecular Diagnostics and its competitors.
Is HTG Molecular Diagnostics' Gross Margin % too high?
HTG Molecular Diagnostics' current Gross Margin % is -11.33%. Overall, HTG Molecular Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does HTG Molecular Diagnostics' Gross Margin % compare to ABMC and TMO?
HTG Molecular Diagnostics' Gross Margin % of -11.33% can be compared against companies in the Medical Diagnostics & Research industry. The industry median Gross Margin % is 50.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on HTG Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HTG Molecular Diagnostics's current Gross Margin % is -11.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HTG Molecular Diagnostics stock overvalued right now?
HTG Molecular Diagnostics (HTGMQ) has a current Gross Margin % of -11.33%. The current Gross Margin % is -11.33%. HTG Molecular Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For HTG Molecular Diagnostics (HTGMQ), the current Gross Margin % is -11.33% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its transcriptome-wide profiling and medicinal chemistry technologies. The company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based HTG EdgeSeq research use only assays and from sample processing services performed in its VERI/O laboratory. The company operates in one segment and its customers and distributors are located in the United States and Europe.
12GF Score
Get the complete analysis for HTGMQ
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTGMQ has been successfully added to your 
